Use of topical glycolic acid plus a lovastatin-cholesterol combination cream for the treatment of autosomal recessive congenital ichthyoses

Abstract

IMPORTANCE Autosomal recessive congenital ichthyosis (ARCI) is a heterogeneous group of disorders caused by defects in signaling pathways involved in epidermal proliferation and differentiation, leading to a wide range of skin manifestations. Therapeutic options are limited and often unsatisfactory. Topical cholesterol and statin as a combined formulation has proven successful in the treatment of patients with CHILD syndrome (congenital hemidysplasia ichthyosis and limb defects). OBJECTIVE To assess change in disease severity score after a 3-month therapeutic regimen consisting of a glycolic acid, 10% to 20%, cream and a combination cream of lovastatin, 2%, with cholesterol, 2%, in the treatment of ARCI. DESIGN, SETTING, AND PARTICIPANTS This case series of 15 patients with ARCI was conducted at the American University of Beirut, a referral center in the Middle East region for genodermatoses, between May 2017 and January 2018. No age groups were excluded; all patients were from the Middle East area; and all were initially not responsive to treatment with hydrating creams in combination with urea creams, 30% to 40%, or glycolic acid, 10% to 20%. Excluded were patients who had been taking systemic retinoids within 3 months before the start of the study. INTERVENTIONS A 3-month therapeutic regimen of glycolic acid, 10% to 20%, cream and a combination of lovastatin, 2%, with cholesterol, 2%, cream. MAIN OUTCOMES AND MEASURES Percentage change in disease severity scores following 2 and 3 months of study treatment. RESULTS Of the 15 patients included in the study, 10 were male (mean age, 11.2 years; age range, 2-38 years). The average percentage reduction in the disease severity score was 33.7% at 2 months (from 60.8 to 40.2) and 57.5% at 3 months (from 60.8 to 21.9). Adverse effects were mild and consisted mainly of irritation and burning. CONCLUSIONS AND RELEVANCE These findings suggest a benefit from a treatment regimen consisting of glycolic acid, 10% to 20%, and a combination of lovastatin, 2%, with cholesterol, 2%, in the treatment of ARCI. This combination of creams might also prove to be beneficial in other types of ichthyoses and other dermatological diseases with a defective skin barrier. © 2018 American Medical Association. All rights reserved.

Description

Keywords

Administration, topical, Adolescent, Adult, Biopsy, Child, Child, preschool, Cholesterol, Drug combinations, Drug therapy, combination, Female, Follow-up studies, Glycolates, Humans, Hydroxymethylglutaryl-coa reductase inhibitors, Ichthyosis, lamellar, Keratolytic agents, Lovastatin, Male, Ointments, Prognosis, Retrospective studies, Severity of illness index, Skin, Young adult, Glycolic acid, Mevinolin, Glycolic acid derivative, Hydroxymethylglutaryl coenzyme a reductase inhibitor, Keratolytic agent, Article, Autosomal recessive congenital ichthyosis, Autosomal recessive disorder, Clinical article, Disease assessment, Disease classification, Disease severity, Drug use, Genodermatosis, Groups by age, Human, Ichthyosis, Middle east, Priority journal, School child, Scoring system, Skin burning sensation, Skin irritation, Treatment duration, Treatment outcome, Treatment response, Combination drug therapy, Drug combination, Follow up, Lamellar ichthyosis, Ointment, Pathology, Preschool child, Retrospective study, Topical drug administration

Citation

Endorsement

Review

Supplemented By

Referenced By